ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!
Search for

UniProtKB/Swiss-Prot entry P13423


[Entry info] [Name and origin] [References] [Comments] [Cross-references] [Keywords] [Features] [Sequence] [Tools]

Note: most headings are clickable, even if they don't appear as links. They link to the user manual or other documents.
Entry information
Entry name PAG_BACAN
Primary accession number P13423
Secondary accession numbers Q937W2 Q937W3 Q9F5R7 Q9KH69 Q9RQU2
Integrated into Swiss-Prot on January 1, 1990
Sequence was last modified on October 18, 2001 (Sequence version 2)
Annotations were last modified on    June 16, 2009 (Entry version 98)
Name and origin of the protein
Protein name Protective antigen [Precursor]
Synonyms PA
PA-83
PA83
Anthrax toxins translocating protein
Contains Protective antigen PA-20
     (PA20)
Protective antigen PA-63
     (PA63)
Gene name
Name: pagA
Synonyms: pag
OrderedLocusNames: pXO1-110, BXA0164, GBAA_pXO1_0164
From
Bacillus anthracis [TaxID: 1392] [HAMAP proteome]
Encoded on Plasmid pXO1.
Taxonomy Bacteria; Firmicutes; Bacillales; Bacillaceae; Bacillus; Bacillus cereus group.
Protein existence 1: Evidence at protein level;
References
[1]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
DOI=10.1016/0378-1119(88)90439-8; PubMed=3148491 [NCBI, ExPASy, EBI, Israel, Japan]
Welkos S.L., Lowe J.R., Eden-Mccutchan F., Vodkin M., Leppla S.H., Schmidt J.J.;
"Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis.";
Gene 69:287-300(1988).
[2]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
STRAIN=28, 33, BA1024, and BA1035;
PubMed=10197996 [NCBI, ExPASy, EBI, Israel, Japan]
Price L.B., Hugh-Jones M., Jackson P.J., Keim P.;
"Genetic diversity in the protective antigen gene of Bacillus anthracis.";
J. Bacteriol. 181:2358-2362(1999).
[3]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
STRAIN=V770-NP1-R / ATCC 14185;
DOI=10.1128/IAI.68.8.4549-4558.2000; PubMed=10899854 [NCBI, ExPASy, EBI, Israel, Japan]
Cohen S., Mendelson I., Altboum Z., Kobiler D., Elhanany E., Bino T., Leitner M., Inbar I., Rosenberg H., Gozes Y., Barak R., Fisher M., Kronman C., Velan B., Shafferman A.;
"Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.";
Infect. Immun. 68:4549-4558(2000).
[4]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
STRAIN=Sterne;
PubMed=10515943 [NCBI, ExPASy, EBI, Israel, Japan]
Okinaka R.T., Cloud K., Hampton O., Hoffmaster A.R., Hill K.K., Keim P., Koehler T.M., Lamke G., Kumano S., Mahillon J., Manter D., Martinez Y., Ricke D., Svensson R., Jackson P.J.;
"Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes.";
J. Bacteriol. 181:6509-6515(1999).
[5]
NUCLEOTIDE SEQUENCE [GENOMIC DNA].
STRAIN=Ames / isolate Florida / A2012;
DOI=10.1126/science.1071837; PubMed=12004073 [NCBI, ExPASy, EBI, Israel, Japan]
Read T.D., Salzberg S.L., Pop M., Shumway M.F., Umayam L., Jiang L., Holtzapple E., Busch J.D., Smith K.L., Schupp J.M., Solomon D., Keim P., Fraser C.M.;
"Comparative genome sequencing for discovery of novel polymorphisms in Bacillus anthracis.";
Science 296:2028-2033(2002).
[6]
NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
STRAIN=Ames ancestor;
Ravel J., Rasko D.A., Shumway M.F., Jiang L., Cer R.Z., Federova N.B., Wilson M., Stanley S., Decker S., Read T.D., Salzberg S.L., Fraser C.M.;
"Bacillus anthracis comparative genomics.";
Submitted (MAY-2004) to the EMBL/GenBank/DDBJ databases.
[7]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 9-751.
STRAIN=Carbosap, and Ferrara;
DOI=10.1046/j.1365-2672.2002.01660.x; PubMed=12067380 [NCBI, ExPASy, EBI, Israel, Japan]
Adone R., Pasquali P., La Rosa G., Marianelli C., Muscillo M., Fasanella A., Francia M., Ciuchini F.;
"Sequence analysis of the genes encoding for the major virulence factors of Bacillus anthracis vaccine strain 'Carbosap'.";
J. Appl. Microbiol. 93:117-121(2002).
[8]
NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 195-434.
STRAIN=PAI;
PubMed=14985634 [NCBI, ExPASy, EBI, Israel, Japan]
Inoue S., Noguchi A., Tanabayashi K., Yamada A.;
"Preparation of a positive control DNA for molecular diagnosis of Bacillus anthracis.";
Jpn. J. Infect. Dis. 57:29-32(2004).
[9]
DOMAINS.
PubMed=1651334 [NCBI, ExPASy, EBI, Israel, Japan]
Singh Y., Klimpel K.R., Quinn C.P., Chaudhary V.K., Leppla S.H.;
"The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity.";
J. Biol. Chem. 266:15493-15497(1991).
[10]
CHARACTERIZATION.
STRAIN=Sterne;
PubMed=8051159 [NCBI, ExPASy, EBI, Israel, Japan]
Milne J.C., Furlong D., Hanna P.C., Wall J.S., Collier R.J.;
"Anthrax protective antigen forms oligomers during intoxication of mammalian cells.";
J. Biol. Chem. 269:20607-20612(1994).
[11]
CHARACTERIZATION.
DOI=10.1046/j.1462-5822.2000.00052.x; PubMed=11207581 [NCBI, ExPASy, EBI, Israel, Japan]
Beauregard K.E., Collier R.J., Swanson J.A.;
"Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization.";
Cell. Microbiol. 2:251-258(2000).
[12]
TOXIN REGULATION.
STRAIN=Weybridge;
PubMed=8300513 [NCBI, ExPASy, EBI, Israel, Japan]
Koehler T.M., Dai Z., Kaufman-Yarbray M.;
"Regulation of the Bacillus anthracis protective antigen gene: CO2 and a trans-acting element activate transcription from one of two promoters.";
J. Bacteriol. 176:586-595(1994).
[13]
FOLDING BY PSRA.
DOI=10.1074/jbc.M301244200; PubMed=12606539 [NCBI, ExPASy, EBI, Israel, Japan]
Williams R.C., Rees M.L., Jacobs M.F., Pragai Z., Thwaite J.E., Baillie L.W., Emmerson P.T., Harwood C.R.;
"Production of Bacillus anthracis protective antigen is dependent on the extracellular chaperone, PrsA.";
J. Biol. Chem. 278:18056-18062(2003).
[14]
INTERACTION WITH ANTHRAX TOXIN RECEPTOR.
DOI=10.1074/jbc.M307900200; PubMed=14507921 [NCBI, ExPASy, EBI, Israel, Japan]
Bradley K.A., Mogridge J., Jonah G., Rainey G.J.A., Batty S., Young J.A.T.;
"Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions.";
J. Biol. Chem. 278:49342-49347(2003).
[15]
MUTAGENESIS OF 342-PHE-PHE-343 AND ASP-344.
STRAIN=Sterne;
PubMed=7961869 [NCBI, ExPASy, EBI, Israel, Japan]
Singh Y., Klimpel K.R., Arora N., Sharma M., Leppla S.H.;
"The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor.";
J. Biol. Chem. 269:29039-29046(1994).
[16]
MUTAGENESIS OF DOMAIN 4 LOOPS.
STRAIN=Sterne;
PubMed=10085028 [NCBI, ExPASy, EBI, Israel, Japan]
Varughese M., Teixeira A.V., Liu S., Leppla S.H.;
"Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin.";
Infect. Immun. 67:1860-1865(1999).
[17]
MUTAGENESIS OF TRP-375; MET-379 AND LEU-381.
STRAIN=Sterne;
DOI=10.1006/bbrc.2001.4320; PubMed=11178978 [NCBI, ExPASy, EBI, Israel, Japan]
Batra S., Gupta P., Chauhan V., Singh A., Bhatnagar R.;
"Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity.";
Biochem. Biophys. Res. Commun. 281:186-192(2001).
[18]
MUTAGENESIS OF PHE-581; PHE-583; ILE-591; LEU-595 AND ILE-603.
STRAIN=Sterne;
DOI=10.1006/bbrc.2001.5613; PubMed=11554763 [NCBI, ExPASy, EBI, Israel, Japan]
Ahuja N., Kumar P., Bhatnagar R.;
"Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are required for oligomerization of anthrax protective antigen.";
Biochem. Biophys. Res. Commun. 287:542-549(2001).
[19]
MUTAGENESIS OF PRO-289.
STRAIN=Sterne;
PubMed=11356563 [NCBI, ExPASy, EBI, Israel, Japan]
Khanna H., Chopra A.P., Arora N., Chaudhry A., Singh Y.;
"Role of residues constituting the 2beta1 strand of domain II in the biological activity of anthrax protective antigen.";
FEMS Microbiol. Lett. 199:27-31(2001).
[20]
MUTAGENESIS OF GLN-512; ASP-541; LEU-543 AND ARG-621.
DOI=10.1128/JB.183.6.2111-2116.2001; PubMed=11222612 [NCBI, ExPASy, EBI, Israel, Japan]
Mogridge J., Mourez M., Collier R.J.;
"Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.";
J. Bacteriol. 183:2111-2116(2001).
[21]
MUTAGENESIS OF LYS-426; ASP-454 AND PHE-456.
DOI=10.1074/jbc.M008309200; PubMed=11113126 [NCBI, ExPASy, EBI, Israel, Japan]
Sellman B.R., Nassi S., Collier R.J.;
"Point mutations in anthrax protective antigen that block translocation.";
J. Biol. Chem. 276:8371-8376(2001).
[22]
MUTAGENESIS OF PRO-213; LEU-216; PHE-231; LEU-232; PRO-234; ILE-236; ILE-239; TRP-255 AND PHE-265.
STRAIN=Sterne;
DOI=10.1128/IAI.70.8.4477-4484.2002; PubMed=12117959 [NCBI, ExPASy, EBI, Israel, Japan]
Chauhan V., Bhatnagar R.;
"Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor.";
Infect. Immun. 70:4477-4484(2002).
[23]
MUTAGENESIS OF ILE-393; THR-409; SER-411; THR-422; LYS-426; ASN-428; TYR-440; ASN-451; ASP-454 AND PHE-456.
DOI=10.1073/pnas.2436299100; PubMed=14623961 [NCBI, ExPASy, EBI, Israel, Japan]
Mourez M., Yan M., Lacy D.B., Dillon L., Bentsen L., Marpoe A., Maurin C., Hotze E., Wigelsworth D., Pimental R.-A., Ballard J.D., Collier R.J., Tweten R.K.;
"Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis.";
Proc. Natl. Acad. Sci. U.S.A. 100:13803-13808(2003).
[24]
MUTAGENESIS OF ASN-686; LYS-708; LYS-709; TYR-710; ASN-711; ASP-712; LYS-713; LEU-714; PRO-715; LEU-716; TYR-717; ILE-718; ASN-720; PRO-721 AND ASN-722.
DOI=10.1074/jbc.M301154200; PubMed=12771151 [NCBI, ExPASy, EBI, Israel, Japan]
Rosovitz M.J., Schuck P., Varughese M., Chopra A.P., Mehra V., Singh Y., McGinnis L.M., Leppla S.H.;
"Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.";
J. Biol. Chem. 278:30936-30944(2003).
[25]
X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS).
DOI=10.1038/385833a0; PubMed=9039918 [NCBI, ExPASy, EBI, Israel, Japan]
Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., Liddington R.C.;
"Crystal structure of the anthrax toxin protective antigen.";
Nature 385:833-838(1997).
[26]
X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 30-764 IN COMPLEX WITH ANTXR2.
DOI=10.1038/nature02763; PubMed=15243628 [NCBI, ExPASy, EBI, Israel, Japan]
Santelli E., Bankston L.A., Leppla S.H., Liddington R.C.;
"Crystal structure of a complex between anthrax toxin and its host cell receptor.";
Nature 430:905-908(2004).
[27]
X-RAY CRYSTALLOGRAPHY (4.3 ANGSTROMS) OF 203-764 IN COMPLEX WITH ANTXR2.
DOI=10.1073/pnas.0405405101; PubMed=15326297 [NCBI, ExPASy, EBI, Israel, Japan]
Lacy D.B., Wigelsworth D.J., Melnyk R.A., Harrison S.C., Collier R.J.;
"Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation.";
Proc. Natl. Acad. Sci. U.S.A. 101:13147-13151(2004).
[28]
REVIEW.
DOI=10.1146/annurev.micro.55.1.647; PubMed=11544370 [NCBI, ExPASy, EBI, Israel, Japan]
Mock M., Fouet A.;
"Anthrax.";
Annu. Rev. Microbiol. 55:647-671(2001).
Comments
  • FUNCTION: One of the three proteins composing the anthrax toxin, the agent which infects many mammalian species and that may cause death. PA binds to a receptor (ATR) in sensitive eukaryotic cells, thereby facilitating the translocation of the enzymatic toxin components, edema factor and lethal factor, across the target cell membrane. PA associated with LF causes death when injected, PA associated with EF produces edema. PA induces immunity to infection with anthrax.
  • SUBUNIT: Anthrax toxins are composed of three distinct proteins, a protective antigen (PA), a lethal factor (LF) and an edema factor (EF). None of these is toxic by itself. PA+LF forms the lethal toxin (LeTx); PA+EF forms the edema toxin (EdTx). PA-63 forms heptamers and this oligomerization is required for LF or EF binding. This complex is endocytosed by the host. Once activated, at low pH, the heptamer undergoes conformational changes and converts from prepore to pore inserted in the membrane, forming cation-selective channels and triggering the release of LF and EF in the host cytoplasm.
  • INTERACTION:
    Q9H6X2-2:ANTXR1 (xeno); NbExp=2; IntAct=EBI-456868, EBI-905659;
    P58335:ANTXR2 (xeno); NbExp=4; IntAct=EBI-456868, EBI-456840;
  • SUBCELLULAR LOCATION: Secreted, extracellular space. Note=Secreted through the Sec-dependent secretion pathway. Therefore, PA is translocated across the membrane in an unfolded state and then it is folded into its native configuration on the trans side of the membrane, prior to its release to the environment. PA requires the extracellular chaperone prsA for efficient folding.
  • DOMAIN: The molecule is folded into four functional domains. Each domain is required for a particular step in the toxicity process. Domain 1 contains two calcium ions and the proteolytic activation site. Cleavage of the PA monomer releases the subdomain 1a, which is the N-terminal fragment of 20-kDa (PA20). The subdomain 1b is part of the remaining 63-kDa fragment (PA63) and contains the binding sites for LP and EF. Domain 2 is a beta-barrel core containing a large flexible loop that has been implicated in membrane insertion and pore formation. There is a chymotrypsin cleavage site in this loop that is required for toxicity. Domain 3 has a hydrophobic patch thought to be involved in protein-protein interactions. Domain 4 appears to be a separate domain and shows limited contact with the other three domains: it would swing out of the way during membrane insertion. It is required for binding to the receptor; the small loop is involved in receptor recognition.
  • PTM: Proteolytic activation by furin or a furin-like protease cleaves the protein in two parts, PA-20 and PA-63; the latter is the mature protein. The cleavage occurs at the cell surface and probably in the serum of infected animals as well; both native and cleaved PA are able to bind to the cell receptor. The release of PA20 from the remaining receptor-bound PA63 exposes the binding site for EF and LF, and promotes oligomerization and internalization of the protein.
  • MISCELLANEOUS: In PubMed:10085028 multiple mutagenesis experiments were performed that showed that the residues present in the small loop of domain 4, and not the ones in the large loop, are involved in receptor recognition. In PubMed:14623961 high-throughput scanning mutagenesis experiments were performed in which all residues of PA-63 were mutated into Cys. Dominantly negative (DN) mutants were all clustered in domain 2. DN mutants prevent the conformational transition of PA-63 from the prepore to the pore state.
  • SIMILARITY: Belongs to the bacterial binary toxin family.
Copyright
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms. Distributed under the Creative Commons Attribution-NoDerivs License.
Cross-references
Sequence databases
EMBL
M22589; AAA22637.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF306778; AAG24446.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF306779; AAG24447.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF306780; AAG24448.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF306781; AAG24449.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF306782; AAG24450.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF306783; AAG24451.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF268967; AAF86457.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AF065404; AAD32414.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AE011190; AAM26109.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AE017336; AAT28905.2; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AJ413936; CAC93934.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AJ413937; CAC93935.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
AB125961; BAD14937.1; -; Genomic_DNA.[EMBL / GenBank / DDBJ] [CoDingSequence]
PIR I39934; I39934.
RefSeq NP_052806.1; -.
NP_652920.1; -.
YP_016495.2; -.
3D structure databases
PDB
1ACC; X-ray; 2.10 A; A=30-764.[ExPASy / RCSB / EBI]
1T6B; X-ray; 2.50 A; X=30-764.[ExPASy / RCSB / EBI]
1TX5; Model; -; C=30-764.[ExPASy / RCSB / EBI]
1TZN; X-ray; 4.30 A; A/B/C/D/E/F/G/H/I/J/K/L/M/O=203-764.[ExPASy / RCSB / EBI]
1TZO; X-ray; 3.60 A; A/B/C/D/E/F/G/H/I/J/K/L/M/O=203-764.[ExPASy / RCSB / EBI]
1V36; Model; -; A/B/C/D/E/F/G=197-764.[ExPASy / RCSB / EBI]
3ETB; X-ray; 3.80 A; J/K/L/M=621-764.[ExPASy / RCSB / EBI]
Detailed list of linked structures.
PDBsum 1ACC; -.
1T6B; -.
1TX5; -.
1TZN; -.
1TZO; -.
1V36; -.
3ETB; -.
ModBase P13423.
Protein-protein interaction databases
IntAct P13423; 5.
Protein family/group databases
TCDB 1.C.42.1.1; channel-forming bacillus anthracis protective antigen (BAPA) family.
Enzyme and pathway databases
BioCyc BANT261594:GBAA_PXO1_0154-MON; -.
Pathway_Interaction_DB anthraxpathway; Cellular roles of Anthrax toxin.
Ontologies
GO
GO:0005615; Cellular component: extracellular space (inferred from electronic annotation from UniProtKB-SubCell).
GO:0005509; Molecular function: calcium ion binding (inferred from electronic annotation from UniProtKB-KW).
GO:0005515; Molecular function: protein binding (inferred from physical interaction from IntAct).
GO:0009405; Biological process: pathogenesis (inferred from electronic annotation from UniProtKB-KW).
QuickGo view.
Family and domain databases
InterPro IPR003896; Bacterial_exotoxin_B.
IPR011658; PA14.
Graphical view of domain structure.
Pfam PF03495; Binary_toxB; 1.
PF07691; PA14; 1.
Pfam graphical view of domain structure.
PRINTS PR01391; BINARYTOXINB.
SMART SM00758; PA14; 1.
SMART graphical view of domain structure.
Genome annotation databases
GeneID 1158723; -.
2820165; -.
3361714; -.
GenomeReviews AE017336_GR; GBAA_pXO1_0164.
KEGG bar:GBAA_pXO1_0164; -.
TIGR GBAA_pXO1_0164; -.
Phylogenomic databases
HOGENOM P13423; -.
Other
PMAP-CutDB P13423; -.
ProtoNet P13423.
UniRef View cluster of proteins with at least 50% / 90% / 100% identity.
Keywords
3D-structure; Calcium; Cleavage on pair of basic residues; Complete proteome; Metal-binding; Plasmid; Secreted; Signal; Toxin; Virulence.
Features
SEVIEWER logo Feature table viewer FT aligner logo Feature aligner
KeyFrom   To Length Description FTId
SIGNAL   1    29  29      
CHAIN   30   764  735     Protective antigen. PRO_0000021996
CHAIN   30   196  167     Protective antigen PA-20. PRO_0000021997
CHAIN   197   764  568     Protective antigen PA-63. PRO_0000021998
REGION   30   287  258     Domain 1, calcium-binding; LF and EF binding sites. 
REGION   288   516  229     Domain 2, membrane insertion and heptamerization. 
REGION   517   624  108     Domain 3, heptamerization. 
REGION   625   764  140     Domain 4, binding to the receptor. 
METAL   206   206        Calcium. 
METAL   208   208        Calcium. 
METAL   210   210        Calcium. 
METAL   217   217        Calcium. 
SITE   196   197  2     Cleavage; by furin. 
SITE   343   344  2     Cleavage; by chymotrypsin; required for translocation of LF and EF. 
SITE   712   712  1     Essential for binding to cell receptor. 
VARIANT   295   295  1     M -> I (in strain: PAI). 
VARIANT   392   392  1     N -> D (in strain: PAI). 
VARIANT   560   560  1     F -> L (in Sverdlovsk sample). 
VARIANT   565   565  1     P -> S (in strain: BA1024). 
VARIANT   600   600  1     A -> V (in strain: BA1024, V770-NP1-R, Carbosap and Ferrara). 
MUTAGEN   213   213        P->A: Decrease in the ability to bind to LF and partially toxic at high concentrations. 
MUTAGEN   216   216        L->A: Decrease in the ability to bind to LF and partially toxic at high concentrations. 
MUTAGEN   231   231        F->A: Loss of ability to bind to LF and completely nontoxic. 
MUTAGEN   232   232        L->A: Loss of ability to bind to LF and completely nontoxic. 
MUTAGEN   234   234        P->A: Loss of ability to bind to LF and completely nontoxic. 
MUTAGEN   236   236        I->A: Loss of ability to bind to LF and completely nontoxic. 
MUTAGEN   239   239        I->A: Decrease in the ability to bind to LF and partially toxic at high concentrations. 
MUTAGEN   255   255        W->A: No effect on LF-binding ability and as toxic as the wild-type. 
MUTAGEN   265   265        F->A: No effect on LF-binding ability and as toxic as the wild-type. 
MUTAGEN   289   289        P->A: Reduced toxicity in combination with lethal factor. Decreased membrane insertion and translocation of LF. 
MUTAGEN   342   344        FFD->AAA: Decrease in toxicity probably due to slow translocation of LF. 
MUTAGEN   342   343        Missing: Loss of toxicity probably due to loss of capability to translocate LF. 
MUTAGEN   342   342        F->C: Loss of toxicity probably due to loss of capability to translocate LF. 
MUTAGEN   344   344        D->A: Decrease in toxicity probably due to slow translocation of LF. 
MUTAGEN   375   375        W->A: Loss of toxicity probably due to faulty membrane insertion or translocation of LF/EF into the cytosol. 
MUTAGEN   379   379        M->A: No effect. 
MUTAGEN   381   381        L->A: Loss of toxicity probably due to faulty membrane insertion or translocation of LF/EF into the cytosol. 
MUTAGEN   393   393        I->C: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   409   409        T->C: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   411   411        S->C: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   422   422        T->C: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   426   426        K->A,D: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   428   428        N->C: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   440   440        Y->C: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   451   451        N->C: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   454   454        D->A,K: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   456   456        F->A: Loss of capability to undergo conformational changes that lead to pore formation and translocation. 
MUTAGEN   512   512        Q->A: Loss of heptamerization capability. 
MUTAGEN   541   541        D->A: Loss of heptamerization capability. 
MUTAGEN   543   543        L->A: Decrease in heptamerization capability. 
MUTAGEN   581   581        F->A: Loss of toxicity due to defective oligomerization. 
MUTAGEN   583   583        F->A: Decrease in toxicity due to defective oligomerization. 
MUTAGEN   591   591        I->A: Loss of toxicity due to defective oligomerization. 
MUTAGEN   595   595        L->A: Loss of toxicity due to defective oligomerization. 
MUTAGEN   603   603        I->A: Loss of toxicity due to defective oligomerization. 
MUTAGEN   621   621        R->A: No effect. 
MUTAGEN   686   686        N->A: Decrease in toxicity due to decrease in cell binding. 
MUTAGEN   708   708        K->A: No effect on toxicity. 
MUTAGEN   709   709        K->A: Slight decrease in toxicity. 
MUTAGEN   710   710        Y->A: Great decrease in toxicity due to decrease in cell binding. 
MUTAGEN   711   711        N->A: Loss of toxicity due to decrease in cell binding. 
MUTAGEN   712   712        D->A: Loss of toxicity due to decrease in cell binding. 
MUTAGEN   713   713        K->A: No effect on toxicity. 
MUTAGEN   714   714        L->A: No effect on toxicity. 
MUTAGEN   715   715        P->A: Great decrease in toxicity due to decrease in cell binding. 
MUTAGEN   716   716        L->A: Decrease in toxicity due to decrease in cell binding. 
MUTAGEN   717   717        Y->A: No effect on toxicity. 
MUTAGEN   718   718        I->A: Decrease in toxicity due to decrease in cell binding. 
MUTAGEN   719   719        S->A: No effect on toxicity. 
MUTAGEN   720   720        N->A: No effect on toxicity. 
MUTAGEN   721   721        P->A: No effect on toxicity. 
MUTAGEN   722   722        N->A: No effect on toxicity. 
CONFLICT   314   314        Q -> E (in Ref. 1; AAA22637). 
STRAND   48    58  11      
STRAND   60    71  12      
HELIX   76    79  4      
HELIX   84    87  4      
STRAND   91   102  12      
STRAND   104   110  7      
HELIX   113   115  3      
STRAND   116   120  5      
STRAND   123   129  7      
STRAND   135   137  3      
STRAND   142   150  9      
STRAND   156   159  4      
STRAND   162   166  5      
STRAND   172   174  3      
TURN   177   179  3      
STRAND   210   212  3      
HELIX   214   219  6      
STRAND   221   225  5      
STRAND   230   234  5      
HELIX   237   240  4      
TURN   241   244  4      
STRAND   259   262  4      
HELIX   264   269  6      
HELIX   279   281  3      
STRAND   291   302  12      
STRAND   318   326  9      
STRAND   357   363  7      
HELIX   375   379  5      
STRAND   386   397  12      
STRAND   399   401  3      
STRAND   410   414  5      
TURN   415   417  3      
STRAND   418   423  6      
STRAND   438   441  4      
STRAND   448   451  4      
STRAND   461   464  4      
HELIX   465   474  10      
STRAND   476   481  6      
STRAND   487   492  6      
TURN   493   496  4      
STRAND   497   505  9      
HELIX   506   515  10      
STRAND   516   522  7      
TURN   524   526  3      
STRAND   530   535  6      
HELIX   552   560  9      
HELIX   576   578  3      
STRAND   579   583  5      
HELIX   585   597  13      
HELIX   603   606  4      
TURN   607   609  3      
STRAND   617   622  6      
STRAND   625   627  3      
STRAND   633   636  4      
HELIX   638   644  7      
STRAND   649   652  4      
STRAND   655   658  4      
HELIX   662   666  5      
STRAND   668   676  9      
STRAND   682   686  5      
STRAND   695   697  3      
STRAND   703   706  4      
HELIX   707   710  4      
TURN   711   713  3      
STRAND   724   731  8      
HELIX   732   734  3      
STRAND   753   759  7      
HELIX   760   763  4      
Sequence information
Length: 764 AA [This is the length of the unprocessed precursor] Molecular weight: 85811 Da [This is the MW of the unprocessed precursor] CRC64: 3AE1EFBF48FAA03F [This is a checksum on the sequence]
        10         20         30         40         50         60 
MKKRKVLIPL MALSTILVSS TGNLEVIQAE VKQENRLLNE SESSSQGLLG YYFSDLNFQA 

        70         80         90        100        110        120 
PMVVTSSTTG DLSIPSSELE NIPSENQYFQ SAIWSGFIKV KKSDEYTFAT SADNHVTMWV 

       130        140        150        160        170        180 
DDQEVINKAS NSNKIRLEKG RLYQIKIQYQ RENPTEKGLD FKLYWTDSQN KKEVISSDNL 

       190        200        210        220        230        240 
QLPELKQKSS NSRKKRSTSA GPTVPDRDND GIPDSLEVEG YTVDVKNKRT FLSPWISNIH 

       250        260        270        280        290        300 
EKKGLTKYKS SPEKWSTASD PYSDFEKVTG RIDKNVSPEA RHPLVAAYPI VHVDMENIIL 

       310        320        330        340        350        360 
SKNEDQSTQN TDSQTRTISK NTSTSRTHTS EVHGNAEVHA SFFDIGGSVS AGFSNSNSST 

       370        380        390        400        410        420 
VAIDHSLSLA GERTWAETMG LNTADTARLN ANIRYVNTGT APIYNVLPTT SLVLGKNQTL 

       430        440        450        460        470        480 
ATIKAKENQL SQILAPNNYY PSKNLAPIAL NAQDDFSSTP ITMNYNQFLE LEKTKQLRLD 

       490        500        510        520        530        540 
TDQVYGNIAT YNFENGRVRV DTGSNWSEVL PQIQETTARI IFNGKDLNLV ERRIAAVNPS 

       550        560        570        580        590        600 
DPLETTKPDM TLKEALKIAF GFNEPNGNLQ YQGKDITEFD FNFDQQTSQN IKNQLAELNA 

       610        620        630        640        650        660 
TNIYTVLDKI KLNAKMNILI RDKRFHYDRN NIAVGADESV VKEAHREVIN SSTEGLLLNI 

       670        680        690        700        710        720 
DKDIRKILSG YIVEIEDTEG LKEVINDRYD MLNISSLRQD GKTFIDFKKY NDKLPLYISN 

       730        740        750        760 
PNYKVNVYAV TKENTIINPS ENGDTSTNGI KKILIFSKKG YEIG 

P13423 in FASTA format

View entry in raw text format (no links)
Report form for errors/updates in this UniProtKB/Swiss-Prot entry

BLAST logo BLAST submission on ExPASy/SIB
or at NCBI (USA)
Tools Sequence analysis tools: ProtParam, ProtScale, Compute pI/Mw, PeptideMass, PeptideCutter, Dotlet (Java)
PROSITE logo ScanProsite, MotifScan SWISS-MODEL Submit a homology modeling request to SWISS-MODEL
NPSA logo NPSA Sequence analysis tools

ExPASy logo ExPASy Home page Site Map Search ExPASy Contact us Swiss-Prot
 Hosted by ca flag CBR Canada Mirror sites: Australia  Brazil  China  Korea  Switzerland
Notice: This page will be replaced with www.uniprot.org. Please send us your feedback!